Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.fabinolife.com | |
Market Cap | 7.14 Cr. | |
Enterprise Value(EV) | 6.60 Cr. | 2022-03 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 0.22 | Trailing Twelve Months Ending 2022-03 |
Price-Earning Ratio (PE) | 151.82 | Trailing Twelve Months Ending 2022-03 |
Industry PE | 32.22 | Trailing Twelve Months Ending 2022-03 |
Book Value / Share | 19.54 | Trailing Twelve Months Ending 2022-03 |
Price to Book Value | 1.74 | Calculated using Price: 34.00 |
Dividend Yield | 0.00 | Period Ending 2022-03 |
No. of Shares Subscribed | 0.21 Cr. | 2,100,000 Shares |
FaceValue | 10 | |
Company Profile | ||
The company is engaged in manufacturing, marketing, trading and packing of pharmaceutical and other wellness focused consumer products. The company's core business is marketing of pharmaceutical formulation & products in domestic market through own distribution network and sales force under own brand name, getting its ayurvedic formulations manufactured through loan licensing facilities, packing, labeling etc. |
1 Day |
|
|
1 Week |
|
|
1 Month |
|
+6.25% |
3 Month |
|
+9.68% |
6 Month |
|
+34.65% |
1 Year |
|
-4.76% |
2 Year |
|
|
5 Year |
|
|
10 Year |
|
4 years | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | 0.02 | 10.80 | 3.05 | 1.74 | |
Return on Capital Employed (%) | 9.44 | 12.36 | 2.92 | 2.48 | |
Return on Assets (%) | 0.00 | 1.14 | 1.04 | 1.37 |
Particulars | 4 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Shh. Funds | 1 | 1 | 1 | 4 | |
Non Curr. Liab. | 0 | 1 | 0 | 0 | |
Curr. Liab. | 8 | 2 | 1 | 0 | |
Minority Int. | |||||
Equity & Liab. | 9 | 4 | 2 | 5 | |
Non Curr. Assets | 1 | 1 | 0 | 0 | |
Curr. Assets | 8 | 3 | 2 | 4 | |
Misc. Exp. not W/O | |||||
Total Assets | 9 | 4 | 2 | 5 |
Particulars | 4 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Net Sales | 3 | 8 | 3 | 4 | |
Other Income | 0 | ||||
Total Income | 3 | 8 | 3 | 4 | |
Total Expenditure | -2 | -7 | -3 | -4 | |
PBIDT | 0 | 0 | 0 | 0 | |
Interest | 0 | 0 | 0 | 0 | |
Depreciation | 0 | 0 | 0 | 0 | |
Taxation | 0 | 0 | 0 | ||
Exceptional Items | |||||
PAT | 0 | 0 | 0 | ||
Adjusted EPS | 5 | 0 | 0 |
Particulars | 4 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | 0 | 2 | 0 | -2 | |
Cash Fr. Inv. | 0 | 0 | 0 | ||
Cash Fr. Finan. | 0 | -2 | 0 | 2 | |
Net Change | 0 | 0 | 1 | ||
Cash & Cash Eqvt | 0 | 0 | 0 | 1 |
Thu, 12 Jan 2023
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Certificate under Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulations 2018 for the quarter ended December 31 2022 dated January 11 2023 received from M/s Bigshare Services Private Limited the Registrar and Share Transfer Agent of the Company. |
Thu, 24 Nov 2022
Board Meeting Outcome for Revised Outcome Of Board Meeting & Submission Of Unaudited Financial Results For Half Year Ended September 30 2022 In continuation of our letter dated November 02 2022 pursuant to regulation 33 read with Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 the Unaudited Financial Results set out in compliance with Accounting Standards (AS) for the Half Year ended September 30 2022 duly approved by the Board of Directors of the Company in their meeting held on November 09 2022 together with Statement of Assets and Liabilities Cash Flow and Limited Review Report thereon are enclosed. |
Wed, 09 Nov 2022
Board Meeting Outcome for Outcome Of Board Meeting - Submission Of Unaudited Financial Results For Half Year Ended September 30 2022 In continuation of our letter dated November 02 2022 pursuant to regulation 33 read with Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 the Unaudited Financial Results set out in compliance with Accounting Standards (AS) for the Half Year ended September 30 2022 duly approved by the Board of Directors of the Company in their meeting held today i.e. November 09 2022 together with Statement of Assets and Liabilities Cash Flow and Limited Review Report thereon are enclosed. |
Fri, 27 Jan 2023 |
|
|
|
|
|